Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

(2008) Zhang Weihua et al.   CANCER CELL

Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer

(2008) T. Okazaki et al.   CLINICAL CANCER RESEARCH

Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

(2008) C. Tibaldi et al.   CLINICAL CANCER RESEARCH

Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells

(2008) E. Giovannetti et al.   MOLECULAR PHARMACOLOGY

Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks

(2008) W. Y. Mansour et al.   NUCLEIC ACIDS RESEARCH

mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines

(2008) Junichi SHIMIZU et al.   RESPIROLOGY

Role of gemcitabine in metastatic breast cancer patients: A short review

(2007) Nicola Silvestris et al.   BREAST